Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
HF4852 makes a series of changes to Minnesota’s Medicaid prescription drug formulary and prior-authorization process. The bill expands and formalizes the role of the Formulary Committee by requiring at least one committee member with rare-disease expertise, adding a representative designated by the Minnesota Rare Disease Advisory Council, and directing the committee to seek that council’s input before acting on prior authorization requirements or preferred drug list placement for orphan drugs. It also requires the Department of Human Services commissioner to create a public comment process for formulary recommendations and to publicly post conflict-of-interest disclosures and public comments on the department website within specified timeframes.
The bill also revises how prior authorization may be imposed on drugs covered by Medical Assistance. It adds notice, review, and public-comment requirements before prior authorization can be required, preserves or expands exceptions for certain mental health drugs, liquid methadone, and oral liquid medications for patients using enteral tubes, and requires a streamlined prior-authorization form for those patients. In addition, it strengthens transparency around the preferred drug list by requiring public notice, hearings, and disclosure of clinical analysis and health-disparity impacts before drugs are removed or modified on the list.
The bill amends Minnesota Statutes section 256B.0625, subdivisions 13c, 13f, and 13g, which govern the Medicaid Formulary Committee, prior authorization, and the preferred drug list. It changes committee membership and conflict-of-interest rules, expands public disclosure obligations, and adds procedural requirements before the commissioner can impose or continue prior authorization or alter the preferred drug list. The bill also limits pharmacy benefit manager contracting to the extent necessary to preserve the committee’s ability to consult with the Rare Disease Advisory Council, and it creates new administrative duties for the Department of Human Services related to public comments, hearings, notices, and documentation.
The bill appears generally supportive of greater transparency, public participation, and rare-disease input in drug coverage decisions. Its structure suggests an effort to balance cost-control tools like prior authorization with patient access concerns, especially for people with rare diseases, disabilities, mental illness, and enteral-tube medication needs. No committee transcript or vote history was provided, so there is no recorded floor or committee sentiment beyond the bill’s stated policy direction.
The main points of contention are likely to be around conflicts of interest, the scope of public participation, and the degree to which the commissioner and Formulary Committee can use prior authorization and preferred drug list changes to manage costs. The bill explicitly allows members with a potential conflict to participate in communications and discussions so long as they recuse from matters where a conflict exists, which may draw concern from those favoring stricter recusal rules. Another likely issue is the added procedural burden on DHS and the limits placed on pharmacy benefit manager contracts, which could be viewed as reducing administrative flexibility. On the other hand, patient advocates and rare-disease stakeholders are likely to support the added transparency and mandatory consultation requirements.